logo logo

ABOUT US

Company Overview

ABOUT US

Company Overview

Company History

  1. Company Overview
  2. Company History

Privacy Policy

닫기

Email Collection Refusal

닫기
BIOTEN HISTORY At Bioten, our journey has been dedicated to the
health and well-being of humanity.
  1. ~2023
    1. 2023
      • KONEX listing
      • Launched our original brand, 'TenQmin'
      • Research findings on the potential treatment of COVID-19 were published in the February issue of the International Journal of Immunopharmacology
    2. 2022
      • Achieved annual sales exceeding 10 billion won in 2022
    3. 2021
      • Initiated exports to Chile, Bangladesh, and Taiwan
      • Selected for a pilot project in Jeollabuk-do for reducing avian influenza (AI)
    4. 2020
      • Concluded manufacturing, sales, and supply agreement with PharmGen Science Corp. (formerly Wooridul Pharmaceuticals, Inc.)
      • Successfully obtained IND approval for Phase 1 clinical trials of a rotavirus treatment
  2. 2017 ~ 2019
    1. 2019
      • Designated as a member of the Korea Institute of Life Sciences family of enterprises
    2. 2017
      • Concluded a technology transfer agreement for a composition for the prevention or treatment of rotavirus (with the Korea Institute of Life Sciences)
  3. 2014 ~ 2016
    1. 2016
      • Concluded a technology transfer agreement for the solubilization technology of hydrophobic substances
        (with the Korea Institute of Life Sciences)
      • Selected as a supported company for the Korea Institute of Life Sciences' Creative Technology Commercialization Project
        (Emerging Hidden Champions)
    2. 2015
      • Certified as a technology innovation-oriented small and medium enterprise (Innobiz)
    3. 2014
      • Acquired ISO 9001 certification
  4. 2011 ~ 2013
    1. 2013
      • Concluded a technology transfer agreement for the immune-boosting material KR-500
        (with the Korea Institute of Life Sciences)
    2. 2012
      • Achieved venture company certification
      • Accomplished overseas exports (to Malaysia)
      • Applied for manufacturing authorization of veterinary ancillary products (disinfectants)
    3. 2011
      • Concluded a technology transfer agreement for the antiviral material KW-100
        (with the Korea Institute of Life Sciences)
      • Established an in-house research and development center
      • Company establishment (Bioten)

Place an Order